TAU-284 — Competitive Intelligence Brief

TAU-284 (TAU-284) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tau aggregation inhibitor. Area: Neurology.

phase 3 Tau aggregation inhibitor Tau protein Neurology Small molecule

Target snapshot

TAU-284 (TAU-284) — Tanabe Pharma Corporation. Tau-284 is a tau aggregation inhibitor.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TAU-284 TARGET	TAU-284	Tanabe Pharma Corporation	phase 3	Tau aggregation inhibitor	Tau protein
TAU	TAU	Montefiore Medical Center	marketed	Tau protein aggregation inhibitor	Tau protein
RVT-101	RVT-101	Axovant Sciences Ltd.	phase 3	tau protein inhibitor	tau protein
Tau PET scan using MK-6240	Tau PET scan using MK-6240	University of California, Irvine	phase 3	PET imaging agent	Tau protein (paired helical filaments)
TRx0237	TRx0237	TauRx Therapeutics Ltd	phase 3	tau aggregation inhibitor	tau protein
Experimental: ALZ-801	Experimental: ALZ-801	Alzheon Inc.	phase 3	Tau aggregation inhibitor	Tau protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tau aggregation inhibitor class)

1. AC Immune SA · 1 drug in this class
2. Alzheon Inc. · 1 drug in this class
3. Tanabe Pharma Corporation · 1 drug in this class